Analysis of the KRAS Mutant Cancer Pipeline, 2024: Emerging Therapies, Key Players, Unmet Needs and More

Dublin, May 30, 2024 (GLOBE NEWSWIRE) -- The "KRAS Mutant Cancer - Pipeline Insight, 2024" drug pipelines has been added to's offering.

This report outlays comprehensive insights of present clinical development scenario and growth prospects across the KRAS Mutant Cancer market. A detailed picture of the KRAS Mutant Cancer pipeline landscape is provided, which includes the disease overview and KRAS Mutant Cancer treatment guidelines.

The assessment part of the report embraces in-depth KRAS Mutant Cancer commercial assessment and clinical assessment of the KRAS Mutant Cancer pipeline products from the pre-clinical developmental phase to the marketed phase.

In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, KRAS Mutant Cancer collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

The report provides insights into:

  • All of the companies that are developing therapies for the treatment of KRAS Mutant Cancer with aggregate therapies developed by each company for the same.
  • Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the KRAS Mutant Cancer treatment.
  • KRAS Mutant Cancer key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of KRAS Mutant Cancer market.

Key Questions Answered

  • What are the current options for KRAS Mutant Cancer treatment?
  • How many companies are developing therapies for the treatment of KRAS Mutant Cancer?
  • What are the principal therapies developed by these companies in the industry?
  • How many therapies are developed by each company for the treatment of KRAS Mutant Cancer?
  • How many KRAS Mutant Cancer emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of KRAS Mutant Cancer?
  • Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact KRAS Mutant Cancer market?
  • Which are the dormant and discontinued products and the reasons for the same?
  • What is the unmet need for current therapies for the treatment of KRAS Mutant Cancer?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing KRAS Mutant Cancer therapies?
  • What are the clinical studies going on for KRAS Mutant Cancer and their status?
  • What are the results of the clinical studies and their safety and efficacy?
  • What are the key designations that have been granted for the emerging therapies for KRAS Mutant Cancer?
  • How many patents are granted and pending for the emerging therapies for the treatment of KRAS Mutant Cancer?

Key Topics Covered

1. Report Introduction
2. KRAS Mutant Cancer
3. KRAS Mutant Cancer Current Treatment Patterns
4. KRAS Mutant Cancer - Analytical Perspective
5. Therapeutic Assessment
6. KRAS Mutant Cancer Late Stage Products (Phase-III)
7. KRAS Mutant Cancer Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. KRAS Mutant Cancer Discontinued Products
13. KRAS Mutant Cancer Product Profiles
14. KRAS Mutant Cancer Key Companies
15. KRAS Mutant Cancer Key Products
16. Dormant and Discontinued Products
17. KRAS Mutant Cancer Unmet Needs
18. KRAS Mutant Cancer Future Perspectives
19. KRAS Mutant Cancer Analyst Review
20. Appendix
21. Report Methodology

For more information about this drug pipelines report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.